LONDON--Drugs that combat obesity could for the first time be included on the World Health Organization’s “essential medicines list,” used to guide government purchasing decisions in low ...
Dr. Carroll is the chief health officer of Indiana University and writes often on health policy. We like to think we understand the drugs we take, especially after rigorous trials have proved ...
The data demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk's Ozempic and Wegovy.
We like to think we understand the drugs we take, especially after rigorous trials have proved their efficacy and safety. But sometimes, we know only that medications work; we just don’t know why.
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the ...
Among today's obesity drugs, Wegovy (semaglutide) produces the greatest weight loss in teenagers, but a study by Columbia researchers has found that the trendy obesity drug is not cost-effective ...
We’ll send you a myFT Daily Digest email rounding up the latest The FT View news every morning. It is somewhat ironic that Denmark’s economic growth in the first half of the year was driven ...
Annual sales of anti-obesity drugs, which today total about $2.2 billion, could reach more than $40 billion globally by 2030, according to Bloomberg analysts. More stories like this are available ...
Poor Weight Loss After Bariatric Surgery? Liraglutide May Help Added weight loss with liraglutide is 'extremely welcomed,' with new antiobesity medications being 'another effective tool in the ...
Sep. 21, 2023 — Obesity surgery is associated with a 40% lower risk of haematological cancer. This has been shown in a study at the University of Gothenburg. This clear link is expected to ...
Alert FDA Okays First Biosimilar for Multiple Sclerosis Sandoz's natalizumab-sztn injection (Tyruko) is on par with Biogen's Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA ...
